Drug intelligence / Profile preview

TRXE-0025

Development stage: Preclinical
Lead developer: Kazia Therapeutics
Modality: Small Molecules

Overview

**TRXE-0025** is a synthetic **super-benzopyran (SBP)** drug candidate developed by Novogen (now Kazia Therapeutics). It belongs to a novel chemical class of increasing structural complexity designed for oncology applications. Specific details on its mechanism of action, primary indications, or clinical progress are limited in available sources, which primarily reference it alongside pipeline companions TRXE-002 (targeting ovarian cancer and malignant ascites) and TRXE-009 (brain cancer and melanoma).[1][3][5][15]

Brand names: Trilexium

Targets

EIF2AK (Eukaryotic translation initiation factor 2-alpha kinase)OXPHOS (Mitochondrial OXPHOS complexes)

Beyond the preview

Go deeper on TRXE-0025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRXE-0025.

Explore the full profile